Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Effects of an alpha 7-nicotinic agonist on default network activity in schizophrenia.

Tregellas JR, Tanabe J, Rojas DC, Shatti S, Olincy A, Johnson L, Martin LF, Soti F, Kem WR, Leonard S, Freedman R.

Biol Psychiatry. 2011 Jan 1;69(1):7-11. doi: 10.1016/j.biopsych.2010.07.004. Epub 2010 Aug 21.

2.

A computational study of the binding of 3-(arylidene) anabaseines to two major brain nicotinic acetylcholine receptors and to the acetylcholine binding protein.

Slavov SH, Radzvilovits M, LeFrancois S, Stoyanova-Slavova IB, Soti F, Kem WR, Katritzky AR.

Eur J Med Chem. 2010 Jun;45(6):2433-46. doi: 10.1016/j.ejmech.2010.02.027. Epub 2010 Feb 13.

PMID:
20236734
3.

Functional magnetic resonance imaging of effects of a nicotinic agonist in schizophrenia.

Tregellas JR, Olincy A, Johnson L, Tanabe J, Shatti S, Martin LF, Singel D, Du YP, Soti F, Kem WR, Freedman R.

Neuropsychopharmacology. 2010 Mar;35(4):938-42. doi: 10.1038/npp.2009.196. Epub 2009 Dec 2.

4.

Positive modulation of alpha7 nAChR responses in rat hippocampal interneurons to full agonists and the alpha7-selective partial agonists, 4OH-GTS-21 and S 24795.

López-Hernández GY, Thinschmidt JS, Morain P, Trocme-Thibierge C, Kem WR, Soti F, Papke RL.

Neuropharmacology. 2009 Mar;56(4):821-30.

5.

Activation and desensitization of nicotinic alpha7-type acetylcholine receptors by benzylidene anabaseines and nicotine.

Papke RL, Kem WR, Soti F, López-Hernández GY, Horenstein NA.

J Pharmacol Exp Ther. 2009 May;329(2):791-807. doi: 10.1124/jpet.108.150151. Epub 2009 Feb 17.

6.

Nicotine analog inhibition of nicotine self-administration in rats.

Rowland NE, Robertson K, Soti F, Kem WR.

Psychopharmacology (Berl). 2008 Sep;199(4):605-13. doi: 10.1007/s00213-008-1186-8. Epub 2008 Jun 7.

PMID:
18536909
7.

Initial phase 2 trial of a nicotinic agonist in schizophrenia.

Freedman R, Olincy A, Buchanan RW, Harris JG, Gold JM, Johnson L, Allensworth D, Guzman-Bonilla A, Clement B, Ball MP, Kutnick J, Pender V, Martin LF, Stevens KE, Wagner BD, Zerbe GO, Soti F, Kem WR.

Am J Psychiatry. 2008 Aug;165(8):1040-7. doi: 10.1176/appi.ajp.2008.07071135. Epub 2008 Apr 1.

8.

Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia.

Olincy A, Harris JG, Johnson LL, Pender V, Kongs S, Allensworth D, Ellis J, Zerbe GO, Leonard S, Stevens KE, Stevens JO, Martin L, Adler LE, Soti F, Kem WR, Freedman R.

Arch Gen Psychiatry. 2006 Jun;63(6):630-8.

PMID:
16754836
9.

N-terminal domains in mouse and human 5-hydroxytryptamine3A receptors confer partial agonist and antagonist properties to benzylidene analogs of anabaseine.

Zhang R, White NA, Soti FS, Kem WR, Machu TK.

J Pharmacol Exp Ther. 2006 Jun;317(3):1276-84. Epub 2006 Mar 21.

PMID:
16551836
10.

Relative toxicities and neuromuscular nicotinic receptor agonistic potencies of anabasine enantiomers and anabaseine.

Lee ST, Wildeboer K, Panter KE, Kem WR, Gardner DR, Molyneux RJ, Chang CW, Soti F, Pfister JA.

Neurotoxicol Teratol. 2006 Mar-Apr;28(2):220-8. Epub 2006 Feb 20.

PMID:
16488116
11.

Hydroxy metabolites of the Alzheimer's drug candidate 3-[(2,4-dimethoxy)benzylidene]-anabaseine dihydrochloride (GTS-21): their molecular properties, interactions with brain nicotinic receptors, and brain penetration.

Kem WR, Mahnir VM, Prokai L, Papke RL, Cao X, LeFrancois S, Wildeboer K, Prokai-Tatrai K, Porter-Papke J, Soti F.

Mol Pharmacol. 2004 Jan;65(1):56-67.

PMID:
14722237
12.

Supplemental Content

Loading ...
Support Center